A Trial Evaluating the Pharmacodynamic Response of NN1250 at Steady State in Subjects With Type 2 Diabetes.
Phase of Trial: Phase I
Latest Information Update: 31 Jan 2017
At a glance
- Drugs Insulin degludec (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Sponsors Novo Nordisk
- 05 Oct 2012 Results from the 0.6 U/kg group (n=16) presented at the 48th Annual Meeting of the European Association for the Study of Diabetes.
- 12 Jun 2012 Results of this and one other trial presented at the 72nd Annual Scientific Sessions of the American Diabetes Association.
- 08 Dec 2011 Results presented at the 21st World Diabetes Congress.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History